News

News 10.03.2022 Zurich-Schlieren, Switzerland, March 10, 2022 - Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that the group of Prof. J Morote Robles from the Vall d’Hebron University Hospital in Barcelona, Spain published significant new clinical study results of Proclarix® in combination with MRI for improved prostate...

News 02.03.2022 Zurich, Switzerland - 01.03.2022 Neurimmune AG has closed an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin. NI006 is designed to directly address the pathology of transthyretin amyloid cardiomyopathy (ATTR-CM) by enabling removal of amyloid fibril deposits...

News 21.02.2022 Schlieren, Switzerland – February 16, 2022 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the close of an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination of strategic and financial...

News 10.02.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, was informed by its partner Novartis that the company...

Events, Internal events
Event date: 18.03.2022 Webinar 1 is available now. New webinars get available every 2 weeks. In today’s competitive environment, the gene to First In Human (FIH) journey is complicated and more challenging than ever. Competitors are chasing the same indications as well as the finite funding available. There is increased pressure to get the...